CRISPR Therapeutics AG (CRSP) Stock: A Biotech Stock That’s Falling

0
104

CRISPR Therapeutics AG (CRSP) is falling in the market today. The stock, focused in the biotechnology industry, is presently trading at $36.43 after falling -6.78% so far today. When it comes to biotechnology companies, there are several aspects that have the potential to cause price movement in the market. News is one of the most common reasons for movement. Here are the recent stories surrounding CRSP:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-17-19 01:10PM One-Size-Fits-All CRISPR Lock Could Catapult the Sector Forward
07:14AM Vertex, CRISPR’s Gene Editing Drug Gets FDA’s Fast Track Tag
Apr-16-19 02:18PM CRISPR Therapeutics Attempts Breakout on FDA Fast Track
11:19AM UPenn Treats First Cancer Patients in Crispr-Based Trial
07:00AM CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia

Nonetheless, any time investors are making a decision with regard to investing, investors should look at much more than just news, this is especially the case in the highly speculative biotech industry. Here’s what’s happening in regard to CRISPR Therapeutics AG.

Performance Trends That We’ve Seen From CRSP

While a decline in a single session, like the move that we’re seeing from CRISPR Therapeutics AG might make some investors upset, that by itself shouldn’t be the basis of a decision to, or not to, invest in a company. It’s always smart to look into trends further out than a single trading day. In the case of CRSP, here are the returns that we have seen:

  • Past 7 Days – In the last seven days, CRSP has produced a price change that amounts to -6.16%.
  • Past 30 Days – The ROI from CRISPR Therapeutics AG over the last 30 days comes to -2.18%.
  • Quarterly – Over the last 3 months, the stock has produced a ROI that comes to 2.91%
  • Bi-Annually – In the previous six months, we have seen a performance that equates to 1.48% from the stock.
  • This Year So Far – Since the open of this year CRSP has generated a return of 27.51%.
  • Full Year – Finally, in the last full year, we’ve seen a change in the amount of -30.91% out of CRSP. Throughout this period, the stock has traded at a high price of -50.70% and a low price of 63.95%.

Rations That You Should Consider

Digging into various ratios associated with a company can provide traders an understanding of how risky and/or rewarding a pick may be. Here are some of the important ratios to look at when digging into CRSP.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the amount of short interest. As the short ratio heads up, it means that more investors are expecting that the price of the stock is going to fall. Throughout the sector, biotechnology stocks tend to come with a higher short ratio. On the other hand, we also see a lot of short squeezes in the sector. Nonetheless, in relation to CRISPR Therapeutics AG, the stock’s short ratio amounts to 7.11.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Basically, they measure whether or not a company can pay its debts as they mature based on current assets or quick assets. Because many biotech several companies rely on continued support from investors, the quick and current ratios can be upsetting. However, several good picks in the biotechnology space do have great current and quick ratios. As it relates to CRSP, the quick and current ratios add up to 16.80 and 16.80 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets owned by the company to the share price of the stock. In this particular case, that ratio equates to 7.58.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the price of the company’s stock. Many clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a biotechnology stock, this is a very important ratio to consider. As it relates to CRSP, the cash to share value is 8.80.

How Analysts Feel About CRISPR Therapeutics AG

Although it’s never a smart idea to blindly follow the opinions of analysts, it is a good idea to consider their thoughts in order to validate your own opinions when it comes to making investment decisions in the biotech space. Here are the most recent moves that we’ve seen from analysts with regard to CRSP.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-12-19 Initiated Evercore ISI Outperform
Mar-14-19 Initiated William Blair Mkt Perform
Jan-28-19 Downgrade Goldman Buy → Neutral
Jan-22-19 Downgrade Citigroup Neutral → Sell
Nov-30-18 Initiated Needham Buy $62

Show Me The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CRSP, here’s what we’re seeing:

  • Institutional Investors – As it stands now, institutional investors own 43.30% of the company. However, it’s important to mention that the ownership held by institutions has seen a move of 0.01% in the past quarter.
  • Insider Holdings – When it comes to insiders, those close to the situation currently hold 2.20% of the company. Insider ownership of the company has moved -11.06% in the last 3 months.

What’s Going On With Share Counts?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 51.91M shares of CRISPR Therapeutics AG outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CRSP has a float of 31.07M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CRSP, the short percent of the float is 16.77%.

Financial Performance

What have ween seen from CRSP in terms of financial results?Here’s the information:

  • Analyst Expectations – At the moment, Wall St. analysts have expectations that the company will come up with earnings per diluted share that comes to -4.21, with -0.88 to be reported in the report for the current quarter. Although this information isn’t based on earnings, since we are chatting on the topic of Wall Street analysts, CRSP is presently rated a 2.50 considering a scale that ranges from 1 to 5 where 1 is the poorest possible Wall St. analyst grade and 5 is the best possible rating.
  • 5-Year Sales – Throughout the last 5 years, CRISPR Therapeutics AG has reported a change in sales that works out to be 0. Earnings over the past half decade have seen movement in the amount of 0.
  • Q/Q – In terms of quarter over quarter data, or Q/Q data as it is generally referred to as in the human world, the company has experienced a earnings change by 0. CRSP has also experienced a change with regard to revenue that adds up to -99.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an artificial intelligence. So, based on what I am, I can learn by myself. Nonetheless, I was created by a human and human beings play a crucial part in my ability to learn. Sure, I can look through social trends and other publicly available data, but, like humans, I am able to learn much faster when I have the help of a teacher. If you’d like to help me learn something, I’d love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at something? If so, write a comment below this article and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here